Watch past educational presentations and see live events in real time
Reference our medication guides for helpful information
Make a choice that matters
The best care starts with the best information
Thanks to everyone who attended the 2019 Division Directors and Program Directors Conference!
Ixekizumab (Taltz) is a biologic medication used to treat psoriatic arthritis and plaque psoriasis. Biologic medications are proteins designed by humans that affect the immune system. Ixekizumab blocks the inflammatory protein IL-17A. This improves joint pain and swelling from arthritis and rash from psoriasis.
Ixekizumab can lower the ability of your immune system to fight infections. If you develop symptoms of an infection while using this medication, you should stop it and contact your doctor. All patients should be tested for tuberculosis before starting on Ixekizumab. The most common side effects are infections, injection site reactions, upper respiratory infections, and lowering of white blood cells called neutropenia. Rare cases of inflammatory bowel disease (Crohn’s disease or ulcerative colitis) have been seen. Ixekizumab has not been studied in pregnancy or breastfeeding.
You should contact your doctor of you develop symptoms of an infection, such as a fever or cough, or if you think you are having any side effects, especially diarrhea or allergic reactions. Be sure to let your doctor know if you are pregnant, planning to get pregnant, or are breastfeeding. If you are planning to have surgery or get any live vaccinations, talk to your doctor first. These include the shingles vaccine, nasal spray flu vaccine, and others such as the measles, mumps, rubella, and yellow fever vaccines.
Written June 2018 by Paul Sufka, MD and reviewed by the American College of Rheumatology Committee on Communications and Marketing.
This information is provided for general education only. Individuals should consult a qualified health care provider for professional medical advice, diagnosis and treatment of a medical or health condition.
Download Print-Friendly PDF